Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zepp Health CorpZEPP · Entity 7017 | Chief Financial Officer | April 01, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zepp Health Corp
Report date April 01, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American depositary sharesSEC Table I · non-derivative | Direct | 124,375 |
Reported balance
After 2026-06-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-26 · Exercise / conversion · Acquired 22,875 · Balance 124,375 F1: These American depositary shares (ADSs), each representing 16 Class A ordinary shares, were acquired upon vesting and settlement of the restricted share units. |
| American depositary sharesSEC Table I · non-derivative | Direct | 114,539 |
Reported balance
After 2026-06-26 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-26 · Sale · Disposed 9,836 · Balance 114,539 F2: The ADSs were sold in a sell-to-cover transaction to cover tax withholding obligations in connection with the vesting and settlement of the restricted share units. F3: The price reported represents the weighted average sale price. These ADSs were sold in multiple transactions at prices ranging from $4.31 to $4.8034 per ADS. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2036-04-01 | Direct | 366,000 |
Reported balance
After 2026-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-01 · Grant · Acquired 366,000 · Balance 366,000 F4: Each restricted share unit represents the contingent right to receive one Class A ordinary share. F5: These restricted share units were granted on April 1, 2026 and vested on June 26, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2036-04-01 | Direct | 0 |
Reported balance
After 2026-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-26 · Exercise / conversion · Disposed 366,000 · Balance 0 F4: Each restricted share unit represents the contingent right to receive one Class A ordinary share. F5: These restricted share units were granted on April 1, 2026 and vested on June 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These American depositary shares (ADSs), each representing 16 Class A ordinary shares, were acquired upon vesting and settlement of the restricted share units.
F2: The ADSs were sold in a sell-to-cover transaction to cover tax withholding obligations in connection with the vesting and settlement of the restricted share units.
F3: The price reported represents the weighted average sale price. These ADSs were sold in multiple transactions at prices ranging from $4.31 to $4.8034 per ADS. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote.
F4: Each restricted share unit represents the contingent right to receive one Class A ordinary share.
F5: These restricted share units were granted on April 1, 2026 and vested on June 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 10:53 UTC | Zepp Health Corp ZEPP · Entity 7017 | Exercise / conversionRestricted Share Units · Derivative | 366,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078469 · tm2619280-1_4seq1.xml · derivative · entry 4 Deng Cheng · CIK 0002113232 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 366,000 shares Expires 2036-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one Class A ordinary share. F5 · derivative.exercise_date: These restricted share units were granted on April 1, 2026 and vested on June 26, 2026. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 10:53 UTC | Zepp Health Corp ZEPP · Entity 7017 | SaleAmerican depositary shares | 9,836 | $4.61 | $45,343.96 |
DisclosureSEC source: 0001104659-26-078469 · tm2619280-1_4seq1.xml · nonDerivative · entry 2 Deng Cheng · CIK 0002113232 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,539 F2 · security: The ADSs were sold in a sell-to-cover transaction to cover tax withholding obligations in connection with the vesting and settlement of the restricted share units. F3 · price: The price reported represents the weighted average sale price. These ADSs were sold in multiple transactions at prices ranging from $4.31 to $4.8034 per ADS. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 10:53 UTC | Zepp Health Corp ZEPP · Entity 7017 | Exercise / conversionAmerican depositary shares | 22,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078469 · tm2619280-1_4seq1.xml · nonDerivative · entry 1 Deng Cheng · CIK 0002113232 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These American depositary shares (ADSs), each representing 16 Class A ordinary shares, were acquired upon vesting and settlement of the restricted share units. Read SEC document |
| April 01, 2026 Filed Jun 29, 2026 10:53 UTC | Zepp Health Corp ZEPP · Entity 7017 | GrantRestricted Share Units · Derivative | 366,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078469 · tm2619280-1_4seq1.xml · derivative · entry 3 Deng Cheng · CIK 0002113232 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,000 Underlying: Class A ordinary shares · 366,000 shares Expires 2036-04-01 F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one Class A ordinary share. F5 · derivative.exercise_date: These restricted share units were granted on April 1, 2026 and vested on June 26, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.